193 related articles for article (PubMed ID: 36368594)
1. Efficacy and Safety of Oral GnRh Antagonists in Patients With Uterine Fibroids: A Systematic Review.
Niaz R; Saeed M; Khan H; Ali MA; Irshad A; Faiz M; Irshad A; Fatima F; Tunio SA; Aiman W
J Obstet Gynaecol Can; 2022 Dec; 44(12):1279-1288. PubMed ID: 36368594
[TBL] [Abstract][Full Text] [Related]
2. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
[TBL] [Abstract][Full Text] [Related]
3. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
4. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
Muhammad J; Yusof Y; Ahmad I; Norhayati MN
BMC Womens Health; 2022 Jan; 22(1):14. PubMed ID: 35033041
[TBL] [Abstract][Full Text] [Related]
5. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
Syed YY
Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
[TBL] [Abstract][Full Text] [Related]
6. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
[TBL] [Abstract][Full Text] [Related]
7. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
Lynch SE; Mayer DC
Ann Pharmacother; 2022 Jan; 56(1):93-101. PubMed ID: 33998300
[TBL] [Abstract][Full Text] [Related]
8. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J; Taylor HS; Stewart EA; Bradley L; Marsh E; Archer D; Al-Hendy A; Petraglia F; Watts N; Gotteland JP; Bestel E; Terrill P; Loumaye E; Humberstone A; Garner E
Lancet; 2022 Sep; 400(10356):896-907. PubMed ID: 36116480
[TBL] [Abstract][Full Text] [Related]
9. Herbal preparations for uterine fibroids.
Liu JP; Yang H; Xia Y; Cardini F
Cochrane Database Syst Rev; 2013 Apr; (4):CD005292. PubMed ID: 23633329
[TBL] [Abstract][Full Text] [Related]
10. Considerations on implementation of the newest treatment for symptomatic uterine fibroids: Oral GnRH antagonists.
de Lange ME; Semmler A; Clark TJ; Mol BWJ; Bet PM; Huirne JAF; Hehenkamp WJK
Br J Clin Pharmacol; 2024 Feb; 90(2):392-405. PubMed ID: 37653680
[TBL] [Abstract][Full Text] [Related]
11. Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Uterine Myomas: A Systematic Review and Network Meta-analysis of Efficacy Parameters and Adverse Effects.
Telek SB; Gurbuz Z; Kalafat E; Ata B
J Minim Invasive Gynecol; 2022 May; 29(5):613-625. PubMed ID: 34942350
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
[TBL] [Abstract][Full Text] [Related]
13. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
[TBL] [Abstract][Full Text] [Related]
14. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.
Ali M; Raslan M; Ciebiera M; Zaręba K; Al-Hendy A
Expert Opin Drug Saf; 2022 Apr; 21(4):477-486. PubMed ID: 34612122
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of oral pharmacotherapeutic options for the management of uterine fibroids.
Rovelli RJ; Cieri-Hutcherson NE; Hutcherson TC
J Am Pharm Assoc (2003); 2022; 62(3):674-682.e5. PubMed ID: 35277362
[TBL] [Abstract][Full Text] [Related]
16. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; A R S; Al Hendy A
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; Chen HY; Chiang YF; Badary OA; Hsia SM; Al-Hendy A
Expert Opin Pharmacother; 2022 Mar; 23(4):421-429. PubMed ID: 35068291
[TBL] [Abstract][Full Text] [Related]
18. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
19. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
Neblett MF; Stewart EA
Obstet Gynecol; 2023 May; 141(5):901-910. PubMed ID: 37103532
[TBL] [Abstract][Full Text] [Related]
20. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS
Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
